Alpha Lipoic Acid Effect on No-Reflow Phenomenon

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

July 1, 2023

Study Completion Date

January 31, 2024

Conditions
No-Reflow Phenomenon
Interventions
DIETARY_SUPPLEMENT

Alpha Lipoic Acid plus the standard care for post-PCI MI

Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

DRUG

The standard care for post-PCI MI

will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

Trial Locations (1)

Unknown

Ain shams hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05360602 - Alpha Lipoic Acid Effect on No-Reflow Phenomenon | Biotech Hunter | Biotech Hunter